周睿, 李莉, 刘旭, 杜冠华. 尾加压素II及其受体的研究进展J. 药学学报, 2016,51(5): 684-689. doi: 10.16438/j.0513-4870.2015-1027
引用本文: 周睿, 李莉, 刘旭, 杜冠华. 尾加压素II及其受体的研究进展J. 药学学报, 2016,51(5): 684-689. doi: 10.16438/j.0513-4870.2015-1027
ZHOU Rui, LI Li, LIU Xu, DU Guan-hua. Research progress of urotensin II and urotensin II receptorJ. Acta Pharmaceutica Sinica, 2016,51(5): 684-689. doi: 10.16438/j.0513-4870.2015-1027
Citation: ZHOU Rui, LI Li, LIU Xu, DU Guan-hua. Research progress of urotensin II and urotensin II receptorJ. Acta Pharmaceutica Sinica, 2016,51(5): 684-689. doi: 10.16438/j.0513-4870.2015-1027

尾加压素II及其受体的研究进展

Research progress of urotensin II and urotensin II receptor

  • 摘要: 尾加压素II(urotensin II, UII) 是目前已报道的体内具有最强收缩血管能力的活性肽, UII 与UII 受体(urotensin II receptor, UT) 广泛分布于中枢及外周的各组织器官中, 发挥多种生理作用。UII/UT系统表达水平的变化与多种疾病进程密切相关, 因此近年来被认为是治疗多种疾病的潜在靶点。本文从配体及受体表达分布、生理活性、病理表现和拮抗剂分类等方面对该系统进行综述。

     

    Abstract: Urotensin II (UII) is the most potent vasoconstrictor among the identified vasoactive peptides. UII and its receptor (UT), which play varies of physiological roles, are widely expressed in central nerve system and peripheral organs. The change on the expressional level of UII/UT system has been proved to be closely correlated with pathological conditions. Therefore, UII/UT system was considered to be a potential target for treating many diseases. This review article is devoted to the latest research progress of UII/UT system in several aspects including ligand and receptor distribution, physiological activity, characteristics under pathological conditions and antagonist classification.

     

/

返回文章
返回